Evidence map›Paper›PMID 25555480›Full record

ArticleInternational journal of hematology2015

A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission.

Minoru Kojima, Naoya Nakamura, Miharu Yabe, Mami Tokunaka, Yara Yukie Kikuti, Tomoki Kikuchi, Hiromichi Murayama, Makiko Moriuchi, Kosuke Tsuboi, Yoshiaki Ogawa and 1 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Minoru KojimaDivision of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1143, Japan, kojima@tokai-u.jp.
Naoya Nakamura
Miharu Yabe
Mami Tokunaka
Yara Yukie Kikuti
Tomoki Kikuchi
Hiromichi Murayama
Makiko Moriuchi
Kosuke Tsuboi
Yoshiaki Ogawa
Kiyoshi Ando
Tokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of HIV-negative Burkitt lymphoma (BL) that relapsed 9 years after complete remission. We performed a polymerase chain reaction analysis of three regions of the VDJ junction of the immunoglobulin heavy chain (IGH) gene and compared the clonality of the first and second BL lesions, which were found to be clonally distinct. The patient received the R-Hyper CVAD/R-MA regimen; however, leukoencephalopathy subsequently developed due to the effect of cytarabine, and the regimen was changed to R-IVAM. The patient achieved complete remission and received high-dose chemotherapy following autologous stem cell transplantation. He maintained the complete remission for 72 months after transplantation. Given this outcome, we suggest that clonally distinct relapse of HIV-negative BL may exhibit a good prognosis.

Indexed as

V(D)J RecombinationAdolescentAntineoplastic Combined Chemotherapy ProtocolsBase SequenceBurkitt LymphomaCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideGenes, ImmunoglobulinHematopoietic Stem Cell TransplantationHumansIfosfamideImmunoglobulin Heavy ChainsMaleCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideIfosfamideImmunoglobulin Heavy ChainsMethotrexateVincristine

Identifiers

PMID25555480
OpenAlexW2006957398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.